We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biosimilar Groups Seek ‘Structural’ Changes in U.S. Market
Biosimilar Groups Seek ‘Structural’ Changes in U.S. Market
Biosimilar groups are pressing federal agencies including the FDA to make “structural” changes to the biosimilar marketplace, claiming that the U.S. is falling far behind Europe on cheaper treatments.